![Ilaria Pagani](/sites/default/files/styles/profile_large/public/profile-images/19888.jpeg?itok=soPiB3Zo)
Ilaria Pagani
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
I am a biomedical researcher in the field of cancer. I previously studied breast cancer and proliferative vitreoretinopathy, but my current and future focus are haematological diseases, in particular chronic myeloid leukaemia (CML). I have a PhD in Experimental Medicine and Oncology, completed in 2012, and I am a Specialist in Medical Genetics, completed in November 2016 with highest honours.
I am a new recipient of the prestigious Beat Cancer Project Mid-career Fellowship valued at $300,000, awarded by the Cancer Council South Australia for the years 2020-2022. I also been awarded the SAHMRI seed funding grant for mid-career researchers valued at $30,000.The aim of my fellowship is identifying and exploiting metabolic dependencies for improved therapeutic outcomes in CML patients. Only ~20% of CML patients are able to achieve optimal outcomes, and 20-30% develop resistance to tyrosine kinase inhibitor therapy or develop fatal blast crisis. This is driven by the failure of current therapies to eradicate leukaemic stem/progenitor cells. My mid-term goal is to develop targeted therapies by re-purposing FDA-approved drugs targeting survival signals and metabolic dependencies in these leukaemic stem/progenitor cells. This approach will enable rapid translation into clinical practice, with an immediate impact on the lives of CML patients.
As Principal Investigator in 2019 I have been awarded the first international-John-Goldman-Research-Award valued at $130,000 for 2 years, beating 29 applicants from 14 countries. The aim of this second project is understanding the causes of treatment free remission after discontinuation of therapy in CML, and identifying patients who can safely cease therapy by using artificial intelligence. This will lead to the development of new targeted therapies for patients predicted to relapse.
I am an Ambassador for the European Association for Cancer Research, promoting the advancement of cancer research for public benefit. I have been recently appointed President of the Association for Research between Italy and Australia, which aim is to diffuse research and create network between researchers, costumers and governments. I am a passionate science communicator, engaging with media and with the community, and I am and advocate for women in STEM.
-
Appointments
Date Position Institution name 2017 - 2020 Affiliated Lecturer University of Adelaide, Adelaide 2015 - 2018 Post-Doctoral Researcher South Australian Health and Medical Research Institute, Adelaide 2014 - 2014 Visiting-Post Doc South Australian Health and Medical Research Institute, Adelaide 2012 - 2014 Post-Doctoral Researcher University of Rome Tor Vergata, Rome 2012 - 2012 Visiting Post-Doc Medical Research Council (MRC), London 2011 - 2012 Post-Doctoral Researcher University of Insubria, Varese -
Awards and Achievements
Date Type Title Institution Name Country Amount 2020 Award Mid-Career Researcher Presentation First Prize SAHMRI Australia - 2019 Award International John Goldman Research Award European School of Haematology (ESH) Australia - 2019 Award ESH Travel Grant covering all expenses European School of Haematology Australia - 2018 Invitation Technical expert/guide to the Italian Delegation in SAHMRI South Australian Health and Medical Research Institute (SAHMRI) Australia - 2018 Invitation Invited speaker to the Cancer in SA Translational Research Meeting, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia. South Australian Health and Medical Research Institute (SAHMRI) Australia - 2018 Award Best poster Award New Directions in Leukaemia Research (NDLR) 2018 Meeting Australia $250 2016 Achievement Invited speaker to the Cancer in SA Translational Research Meeting, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia. South Australian Health and Medical Research Institute (SAHMRI) Australia - 2016 Achievement Invited speaker to the Hematology Seminar, S.A. Pathology, Adelaide, SA, Australia SA Pathology Australia - 2016 Achievement Invited speaker to the 2016 Leukaemia Foundation Patient Education Conference, CML Session, Adelaide University, Australia. Leukaemia Foundation Australia - 2016 Invitation Invited to judge oral/poster presentations for the EMBL Australia Postgraduate Symposium 2016 at SAHMRI, Adelaide, Australia. EMBL Australia Australia - 2016 Award Competitive selective Beat Cancer Project Travel Grant 2016 Cancer Council South Australia Australia $1250 2015 Achievement Invited speaker to the Blood Club Translational Research Meeting, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia. South Australian Health and Medical Research Institute (SAHMRI) Australia - 2014 Award Top 10 Best Abstracts European Society Human Genetics (ESHG), Milan, Italy Italy - 2013 Award American Society of Hematology (ASH) International Post-doctoral Fellow (IPDF) approval and $500 ASH Abstract Achievement Award American Society of Hematology (ASH) Italy $500 2012 Fellowship competitive selective 3 years - Italian Association for Cancer Research" (AIRC) Fellowship Italian Association for Cancer Research (AIRC) Italy - 2011 Award Competitive Selective Travel Fellowship covering all expenses to participate at the 11th FEBS Young Scientist Forum and at 36th FEBS Congress. FEBS Italy - 2011 Fellowship Italian Association against Leukaemia and Lymphoma (AIL) Fellowship Italian Association against Leukaemia and Lymphoma (AIL) Italy - 2007 Scholarship Insubria University PhD Scholarship, Varese, Italy. Insubria University Italy - -
Language Competencies
Language Competency English Can read, write, speak, understand spoken and peer review French Can read, write, speak and understand spoken Italian Can read, write, speak, understand spoken and peer review -
Education
Date Institution name Country Title 2012 University of Insubria, Varese Italy PhD 2011 - 2016 University of Milan, Milan Italy Specialist in Medical Genetics 2007 University of Insubria, Varese Italy Master Degree in Molecular Biology -
Certifications
Date Title Institution name Country 2008 State Examination for the qualification in Biological Science University of Insubria, Varese Italy -
Research Interests
-
Journals
Year Citation 2024 Pellegrino, M., Occhiuzzi, M. A., Grande, F., Pagani, I. S., Aquaro, S., & Tucci, P. (2024). Modulation of energetic and lipid pathways by curcumin as a potential chemopreventive strategy in human prostate cancer cells. Biochemical and Biophysical Research Communications, 735, 150477.
2023 Shanmuganathan, N., Wadham, C., Shahrin, N., Feng, J., Thomson, D., Wang, P., . . . Branford, S. (2023). Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention. Haematologica, 108(9), 2380-2395.
Scopus3 WoS2 Europe PMC32023 Pagani, I. S., Shanmuganathan, N., Dang, P., Saunders, V. A., Grose, R., Kok, C. H., . . . Ross, D. M. (2023). Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy. Blood, 142(25), 2192-2197.
Scopus2 WoS12022 Pagani, I. S., Poudel, G., & Wardill, H. R. (2022). A Gut Instinct on Leukaemia: A New Mechanistic Hypothesis for Microbiota-Immune Crosstalk in Disease Progression and Relapse. Microorganisms, 10(4), 1-14.
Scopus6 WoS1 Europe PMC52022 Bassal, M. A., Samaraweera, S. E., Lim, K., Bernard, B. A., Bailey, S., Kaur, S., . . . D'Andrea, R. J. (2022). Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nature Communications, 13(1), 1-12.
Scopus10 WoS8 Europe PMC92022 Poudel, G., Tolland, M. G., Hughes, T. P., & Pagani, I. S. (2022). Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia. Cancers, 14(14), 18 pages.
Scopus18 WoS10 Europe PMC122022 Bassal, M. A., Samaraweera, S. E., Lim, K., Benard, B. A., Bailey, S., Kaur, S., . . . D'Andrea, R. J. (2022). Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia.. Nat Commun, 13(1), 4131.
Scopus1 WoS12021 Shanmuganathan, N., Pagani, I. S., Ross, D. M., Park, S., Yong, A. S., Braley, J. A., . . . Hughes, T. P. (2021). Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood, 137(9), 1196-1207.
Scopus51 WoS40 Europe PMC252020 Pagani, I. S., Dang, P., Saunders, V. A., Grose, R., Shanmuganathan, N., Kok, C. H., . . . Ross, D. M. (2020). Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. Leukemia, 34(4), 1052-1061.
Scopus37 WoS29 Europe PMC212020 Pagani, I. S., Dang, P., Saunders, V. A., Braley, J., Thieleke, A., Branford, S., . . . Ross, D. M. (2020). Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia. Leukemia and Lymphoma, 61(10), 2527-2529.
Scopus6 WoS4 Europe PMC32019 Ross, D. M., Pagani, I. S., Irani, Y. D., Clarson, J., Leclercq, T., Dang, P., . . . Yong, A. S. M. (2019). Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. British Journal of Haematology, 186(3), e56-e60.
Scopus11 WoS7 Europe PMC82018 Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J. M., Nicola, M., Saunders, V. A., . . . Ross, D. M. (2018). BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. Haematologica, 103(12), 2026-2032.
Scopus31 WoS20 Europe PMC162018 Ross, D., Pagani, I., Shanmuganathan, N., Kok, C., Seymour, J., Mills, A., . . . Hughes, T. (2018). Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia, 32(12), 2572-2579.
Scopus61 WoS46 Europe PMC342017 Pagani, I. S., Kok, C. H., Saunders, V. A., Van der Hoek, M. B., Heatley, S. L., Schwarer, A. P., . . . Ross, D. M. (2017). A method for next-generation sequencing of paired diagnostic and remission Samples to detect mitochondrial DNA mutations associated with leukemia. The Journal of molecular diagnostics : JMD, 19(5), 711-721.
Scopus6 WoS5 Europe PMC52015 Porta, G., Pagani, I. S., & Pirrone, C. (2015). gDNA Q-PCR for clinical monitoring of CML. Cell Cycle, 14(23), 3659-3660.
Scopus6 WoS6 Europe PMC52014 Pagani, I. S., Spinelli, O., Mattarucchi, E., Pirrone, C., Pigni, D., Amelotti, E., . . . Porta, G. (2014). Genomic quantitative real-time PCR proves residual disease posivitity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia. Oncoscience, 1(7), 510-521.
Scopus31 Europe PMC182014 Terrinoni, A., Pagani, I. S., Zucchi, I., Chiaravalli, A. M., Serra, V., Rovera, F., . . . Porta, G. (2014). Erratum: OTX1 expression in breast cancer is regulated by p53 (Oncogene (2011) 30 (3096-3103) doi:10.1038/onc.2011.31). Oncogene, 33(10), 1340.
2013 Azzolini, C., Pagani, I. S., Pirrone, C., Borroni, D., Donati, S., Al Oum, M., . . . Porta, G. (2013). Expression of VEGF-A, otx homeobox and p53 family genes in proliferative vitreoretinopathy. Mediators of Inflammation, 2013, 8 pages.
Scopus23 WoS14 Europe PMC202011 Terrinoni, A., Pagani, I. S., Zucchi, I., Chiaravalli, A. M., Serra, V., Rovera, F., . . . Porta, G. (2011). Erratum: OTX1 expression in breast cancer is regulated by p53 (Oncogene (2011) 30 (3096-3103) DOI: 10.1038/onc.2011.31). Oncogene, 30(27), 3104.
2011 Terrinoni, A., Pagani, I. S., Zucchi, I., Chiaravalli, A. M., Serra, V., Rovera, F., . . . Porta, G. (2011). OTX1 expression in breast cancer is regulated by p53. Oncogene, 30(27), 3096-3103.
Scopus36 WoS33 Europe PMC272011 Pagani, I. S., Terrinoni, A., Marenghi, L., Zucchi, I., Chiaravalli, A. M., Serra, V., . . . Porta, G. (2011). Erratum: The mammary gland and the homeobox gene otx1. (Breast Journal (2010) 16:1 (S53-S56)). Breast Journal, 17(5), 568.
2010 Pagani, I. S., Terrinoni, A., Marenghi, L., Zucchi, I., Chiaravalli, A. M., Serra, V., . . . Porta, G. (2010). The mammary gland and the homeobox gene Otx1. Breast Journal, 16(SUPPL. 1), S53-S56.
Scopus12 WoS9 Europe PMC10 -
Book Chapters
Year Citation 2023 Pagani, I. S., & Torresi, T. (2023). Italian–Australian Scientific and Research Cooperation. In Italy and Australia Redefining Bilateral Relations for the Twenty-First Century (pp. 241-265). Springer Nature Singapore.
-
Conference Papers
Year Citation 2023 Branford, S., Wadham, C., Shanmuganathan, N., Fernandes, A., Shahrin, N. H., Feng, J., . . . Hughes, T. P. (2023). Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML. In BLOOD Vol. 142 (pp. 5 pages). CA, San Diego: AMER SOC HEMATOLOGY.
2022 Poudel, G., Yeung, D. T., White, D. L., Hughes, T., & Pagani, I. S. (2022). <i>PTPN11</i> Mutations Drive Tyrosine Kinase Inhibitor As Well As Venetoclax Resistance in Ph plus ALL Cells, but Are Sensitive to the Combination. In BLOOD Vol. 140 (pp. 3128-3129). LA, New Orleans: AMER SOC HEMATOLOGY.
2018 Leow, B. C., Eadie, L., Pagani, I. S., Yeung, D. T., Hughes, T. P., & White, D. L. (2018). Clonal Selection Determines Resultant Dominance of Tyrosine Kinase Inhibitor-Resistant Cells in Chronic Myeloid Leukaemia. In HemaSphere Vol. 2 (pp. 503). Stockholm, Sweden: Lippincott, Williams & Wilkins.
2017 Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A. K., Filshie, R. J., . . . Hughes, T. P. (2017). Long-term Follow-up of the ALLG CML8 TWISTER Study of Treatment-free Remission (TFR) in Patients With Chronic Myeloid Leukemia (CML).. In Blood Vol. 130 (pp. 1597). Atlanta: American Society of Hematology. 2017 Pagani, I., Dang, P., Kommers, I., Goyne, J., Saunders, V., Prime, J., . . . Ross, D. (2017). Comparison of genomic and reverse transcriptase Q-PCR for the monitoring of first-line imatinib treatment: an ALLG CML9 sub-study. In Haematologica. Madrid: Ferrata Storti Foundation. 2016 Pagani, I. S., Kok, C. H., Saunders, V., Goyne, J., McLean, J., VanderHoek, M., . . . Ross, D. M. (2016). The genomic landscape of mitochondrial DNA mutations in chronic myeloid leukaemia.. In European Journal of Human Genetics. Barcelona: Natue Publishing Group. 2016 Pagani, I. S., Kok, C. H., Wang, J., Saunders, V., Goyne, J., McLean, J., . . . Ross, D. M. (2016). MITOCHONDRIAL DNA MUTATIONS IDENTIFY CLONAL HETEROGENEITY IN CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 101 (pp. 234). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. 2014 Pagani, I. S., Pirrone, C., & Amelotti, E. (2014). TAp73α regulates Otx1 expression during breast cancer stem cells differentiation and in response to cisplatin treatment.. In European Journal of Human Genetics. Milan: Nature Publishing Group. 2014 Pirrone, C., & Pagani, I. S. (2014). New molecular technique to monitor minimal residual diseased in CML. In European Journal of Human Genetics. Milan: Nature Publishing Group. 2014 Pagani, I. S., Spinelli, O., Pirrone, C., Amelotti, E., Lilliu, S., Intermesoli, T., . . . Porta, G. (2014). GENOMIC QUANTITATIVE REAL-TIME PCR ASSAY PROVES RESIDUAL DISEASE POSITIVITY IN MORE THAN 30% SAMPLES WITH NEGATIVE MRNA-BASED QRT-PCR RESULTS IN CHRONIC MYELOID LEUKEMIA. In BONE MARROW TRANSPLANTATION Vol. 49 (pp. S442-S443). Milan, ITALY: NATURE PUBLISHING GROUP. 2013 Pagani, I. S., Spinelli, O., Pirrone, C., Pigni, D., Lupoli, S., D'Avila, F., . . . Porta, G. (2013). Quantitative DNA Real-Time PCR Compared To mRNA and Cytogenetic Assays To Monitor Minimal Residual Disease In Chronic Myeloid Leukemia. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY.
2013 Azzolini, C., & Pagani, I. S. (2013). Expression Of VEGF-A Gene In Normal Retina And In PVR Retina. In Investigative Ophthalmology & Visual Science. Seattle: Association for Research in Vision and Ophthalmology. 2012 Azzolini, C., & Pagani, I. S. (2012). Otx2 And VegfA Expression And P53-Otx1 Differentiation Pathway In Proliferative Vitreoretinopathy. In Investigative Ophthalmology & Visual Science. Fort Lauderdale, Florida, US: Association for Research in Vision and Ophthalmology. 2011 Pagani, I. S., Spinelli, O., Bussini, A., Intermesoli, T., Pasquali, F., Lo Curto, F., . . . Porta, G. (2011). Chronic Myeloid Leukemia: Molecular Monitoring of Residual Disease by Genomic DNA Compared to Conventional mRNA Analysis in Follow-Ups up to 8 Years. In BLOOD Vol. 118 (pp. 733). San Diego, CA: AMER SOC HEMATOLOGY. 2011 Pagani, I. S., Terrinoni, A., Zucchi, I., Chiaravalli, A. M., Serra, V., Rovera, F., . . . Alberti, A. (2011). p53 family members regulate the Otx1 gene expression in differentiation of breast cancer stem cells and in mammary gland development. In FEBS JOURNAL Vol. 278 (pp. 471-472). Torino, ITALY: WILEY-BLACKWELL. 2011 Azzolini, C., Donati, C., Borroni, D., Moriondo, A., & Pagani, I. S. (2011). Evaluation of the p53-Otx1 pathway in the retina.. In Investigative Ophthalmology & Visual Science. Fort Lauderdale, Florida, US: Association for Research in Vision and Ophthalmology. -
Conference Items
Year Citation 2020 Poudel, G., Yeung, D., White, D., Hughes, T., & Pagani, I. (2020). Understanding the mechanisms of imatinib resistance in a Ph+ acute lymphoblastic leukaemia cell line. Poster session presented at the meeting of The 59th ASMR National Scientific Conference. 2018 Pagani, I. S., Kok, C., Saunders, V., Schwarer, A., Hughes, T. P., White, D. L., & Ross, D. M. (2018). Association of mitochondrial DNA (mtDNA) mutations at diagnosis with treatment response in chronic myeloid leukaemia (CML) patients. Poster session presented at the meeting of NDLR. 2017 Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A., Filshie, R., . . . Hughes, T. P. (2017). Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML). Poster session presented at the meeting of 59th ASH Annual Meeting & Exposition.
2021: Pagani IS, Hughes TP. Leukaemia Foundation $102,050, first six-month Strategic Ecosystem Research Partnership grant. "A new precision medicine approach for achieving treatment-free remission in chronic myeloid leukaemia". Award date: 09/2021. 01/09/2021→ 28/02/2022.
2020: Beat Cancer Project COVID-19 Hardship Grant - $8,000-, and 3-months extension of the Beat Cancer project Mid-career fellowship.
2019: Beat Cancer Research Mid-Career Fellowship- $600,000, Granted by Cancer Council South Australia's Beat Cancer Project on behalf of its donors and the State Government of South Australia through the Department of Health and Wellbeing.”'
2019: Pagani IS, Rao SR, Trim P, Ryan F, Lynn D, Ross DM, Thomas D. SAHMRI Mid-Career Seed Funding Grant ($30,000). "Identifying and exploiting metabolic dependencies for improved therapeutic outcomes in chronic myeloid leukaemia patients". Award date: 01/01/2020→ 31/12/2020.
2019: Pagani IS, Ross DM, Hughes TP, Yong A, Branford S, Kok CH, Shanmuganathan N, Gray T, Irani Y. Winner of the First European School of Haematology (ESH) International John Goldman Research Award ($130,000). "Use of machine learning to integrate clinical data and biomarkers to optimize prediction of TFR". Award date: 22/05/19; 1/10/19 → 30/09/21.
2015: David Ross, Ilaria Pagani and Deb White. Contributing Haematologists’ Committee ($200,000). - "Do mitochondrial mutations in chronic myeloid leukaemia identify a pre-leukaemic clone".
2020: I joined Romana Panagopolous delivering workshops in Professor Tania Crotti, 3rd yr. Bch Health and Med Science topic Investigative Cell Biology.
2010: Biochemistry III tutorial, Adelaide University, Australia.
2019: Biochemistry III tutorial, Adelaide University, Australia.
2018: Biochemistry III tutorial, University of Adelaide, Australia.
2016: Biochemistry III tutorial, Adelaide University, Australia.
2007-2013: Lectures and Tutorial of Laboratory Techniques and Genetics to Medical Students, Insubria University, Varese, Italy.
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2024 Principal Supervisor Modelling resistant mutations in Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Ms Zuhal Naderi 2023 Principal Supervisor Investigating the role of lipid metabolism in chronic myeloid leukaemia Doctor of Philosophy Doctorate Full Time Miss Molly Gladys Tolland 2021 Co-Supervisor Genomic Mechanisms Influencing Outcome In Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Miss Adelina Catherina B. Fernandes -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2019 - 2023 Co-Supervisor Unravelling Resistance Mechanisms in Philadelphia Positive Leukemias: Targeted Treatment Strategies to Overcome Resistance Doctor of Philosophy Doctorate Full Time Mr Govinda Poudel -
Other Supervision Activities
Date Role Research Topic Location Program Supervision Type Student Load Student Name 2022 - ongoing Principal Supervisor Exploiting lipid metabolism on chronic myeloid leuakemia SAHMRI Masters of Philosophy Other Full Time Molly Tolland 2019 - 2019 Principal Supervisor Measurement of mitochondrial respiration via seahorse experiments using frozen MNCs from CML patients SAHMRI SAHMRI Summer Research Scholarship Other Full Time Lian Tran 2019 - 2019 Principal Supervisor DNA QPCR assay for the monitoring of minimal residual disease in CML patients SAHMRI SAHMRI Summer Research Scholarship Other Full Time Tarin Ritchie 2018 - ongoing Principal Supervisor Mitochondrial DNA mutations in CML The University of Adelaide Placement Other Part Time Samuel Cannata, Rico Acuna 2018 - ongoing Co-Supervisor Mitochondrial DNA copy Numbers in MPN UniSA Placement Other Part Time Lian Thuy 2017 - ongoing Principal Supervisor Monitoring BCR-ABL content in 2 Chronic Myeloid Leukaemia (CML) Patients Involved in a Trial of Treatment Free Remission (TFR) The University of Adelaide Placement Other Part Time Caitlin Skinner 2014 - ongoing Co-Supervisor Next generation Sequencing in CML Insubria University - Postdoctorate - Pirrone Cristina 2011 - ongoing Principal Supervisor Monitoring of minimal residual disease in CML by gDNA QPCR Insubria University, Varese, Italy - Master Full Time Giorgia Aimoni 2011 - ongoing Principal Supervisor Monitoring of Minimal Residual Disease in CMl Insubria University - Master - Pirrone Cristina 2011 - 2013 Principal Supervisor Next-Generation Sequencing as a new approach to monitor minimal residual disease in CML Insubria University - Doctorate Full Time Pirrone Cristina 2011 - ongoing Co-Supervisor p53-Otx1 in retina Faculty of Medicine, Insubria University, - Master - Borroni Davide 2009 - 2011 Principal Supervisor p53 and Otx1 in Glioblastoma and Breast Cancer Faculty of Medicine, Insubria University Placement Other - Annalisa Paolino, Eleonora Scotti, Martina Baiardo
-
Board Memberships
Date Role Board name Institution name Country 2022 - 2026 Treasurer Committee of Italians Abroad (Com.It.Es) - South Australia Italian Government Australia 2020 - ongoing Board Member Radio Italiana 531 Youth Radio Italiana 531 Australia 2020 - ongoing Founder Association of Italian Researchers in Australasia - ARIA Association not for profit Australia 2020 - ongoing President Association for Italian Researchers in Australasia – South Australia (ARIA). Association for Italian Researchers in Australasia – South Australia (ARIA). Australia 2019 - ongoing Board Member Myeloid Leukaemia Consumer Advisory Gro SAHMRI Australia -
Event Participation
Date Event Name Event Type Institution Country 2021 - ongoing 50th Anniversary of the Italian Republic Receptions Government of South Australia -
Connect With Me
External Profiles